Currently, the only definitive way to determine the HER2 status of breast cancer brain metastases relies upon pathologic tissue sampling via brain biopsy or resection with subsequent immunohistochemical (IHC) and/or fluorescent in situ hybridization (FISH) analyses. The gene discussed is ERBB2; the disease is breast carcinoma.